Rhythm Pharmaceuticals (RYTM) to Release Quarterly Earnings on Wednesday

Rhythm Pharmaceuticals (NASDAQ:RYTM) will likely be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect Rhythm Pharmaceuticals to post earnings of ($0.71) per share and revenue of $38.48 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Rhythm Pharmaceuticals Stock Down 2.9 %

RYTM stock opened at $56.07 on Monday. The business’s fifty day simple moving average is $57.12 and its two-hundred day simple moving average is $54.12. Rhythm Pharmaceuticals has a twelve month low of $35.17 and a twelve month high of $68.58. The firm has a market cap of $3.45 billion, a price-to-earnings ratio of -12.95 and a beta of 2.14.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 1,281 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total value of $76,129.83. Following the completion of the transaction, the insider now directly owns 2,657 shares of the company’s stock, valued at approximately $157,905.51. The trade was a 32.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Hunter C. Smith sold 2,215 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total value of $126,742.30. Following the completion of the sale, the chief financial officer now owns 109,929 shares of the company’s stock, valued at $6,290,137.38. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,787 shares of company stock valued at $1,901,443. 5.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on RYTM shares. JMP Securities reiterated a “market outperform” rating and issued a $75.00 target price on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. TD Cowen lifted their target price on Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Canaccord Genuity Group reiterated a “buy” rating and issued a $80.00 target price on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 19th. The Goldman Sachs Group raised their price target on Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Finally, Oppenheimer assumed coverage on Rhythm Pharmaceuticals in a report on Friday, December 20th. They issued an “outperform” rating and a $76.00 price target for the company. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $68.09.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.